Wymet-GC 80 Tablet PR is a combination oral hypoglycemic agent containing Gliclazide 80 mg and Metformin 500 mg, indicated for the management of type 2 diabetes mellitus, particularly in patients inadequately controlled by diet and exercise alone. Gliclazide, a sulfonylurea derivative, primarily stimulates pancreatic beta-cell insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, improves insulin sensitivity by decreasing hepatic glucose production and enhancing peripheral glucose uptake and utilization. The prolonged-release formulation of Wymet-GC 80 ensures a steady plasma concentration, optimizing glycemic control while minimizing gastrointestinal side effects commonly associated with immediate-release metformin. This combination therapy is beneficial for patients requiring dual mechanisms of action to achieve target glycemic levels. Wymet-GC 80 Tablet PR should be administered with meals to reduce gastrointestinal discomfort. It is contraindicated in patients with renal impairment, hepatic dysfunction, or conditions predisposing to hypoxia or lactic acidosis. Regular monitoring of blood glucose, renal function, and hematological parameters is recommended during therapy. Dose adjustments may be necessary based on therapeutic response and tolerability. Wymet-GC 80 Tablet PR is a valuable therapeutic option for improving glycemic control in type 2 diabetes, contributing to the prevention of microvascular and macrovascular complications.